| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0010-7824(02)00390-6 |
| P698 | PubMed publication ID | 12443967 |
| P2093 | author name string | Zhu H | |
| Anderson RA | |||
| Baird DT | |||
| Cheng L | |||
| P2860 | cites work | Rates of testosterone-induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studies. World Health Organization Task force on Methods for The Regulations of Male Fertility | Q71740479 |
| Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception | Q73258750 | ||
| Oestradiol enhances testosterone-induced suppression of human spermatogenesis | Q73472268 | ||
| Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. | Q33885518 | ||
| Testosterone dose-response relationships in healthy young men. | Q33955919 | ||
| A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. | Q43794522 | ||
| Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. | Q44013158 | ||
| Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. | Q44692016 | ||
| Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido | Q44933545 | ||
| Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. | Q45957208 | ||
| Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. | Q46099617 | ||
| Issues in testosterone replacement in older men. | Q46865270 | ||
| Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations | Q47685007 | ||
| Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism | Q48299089 | ||
| Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study | Q48790823 | ||
| Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. | Q50612224 | ||
| Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. | Q50991440 | ||
| Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. | Q51014706 | ||
| Contraceptive efficacy of testosterone-induced azoospermia in normal men | Q55983041 | ||
| Suppression of human spermatogenesis by testosterone implants | Q56673013 | ||
| Mechanism of Testosterone Action in Erythropoiesis | Q59091935 | ||
| Effect of depot medroxyprogesteroneacetate and testosteroneoenanthate on serum lipoproteins in man | Q61847124 | ||
| Clinical Trial of Transdermal Testosterone and Oral Levonorgestrel for Male Contraception | Q62128443 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 357-364 | |
| P577 | publication date | 2002-11-01 | |
| P1433 | published in | Contraception | Q2995704 |
| P1476 | title | Investigation of a novel preparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonogestrel implants | |
| P478 | volume | 66 |
| Q35871918 | Update on the male hormonal contraceptive agents | cites work | P2860 |
Search more.